Wavelength appoints Seri as company head

Former head of Sun Pharma’s active pharmaceutical ingredients (APIs) operation Iftach Seri has been named as chief executive officer of Wavelength Pharmaceuticals, the APIs business that private investment firm SK Capital recently acquired from Perrigo for US$110 million (Generics bulletin, 1 December 2017, page 2).